Literature DB >> 22249031

Should patients receive general anesthesia prior to extubation at the end of life?.

Robert D Truog1, Dan W Brock, Douglas B White.   

Abstract

Billings has proposed that any potentially conscious and imminently dying patient who is undergoing withdrawal of ventilator support should be offered general anesthesia to fully protect against suffering. Here we examine whether his proposal is compatible with the doctrine of double effect, a philosophical construct that is generally in accord with the legal requirements for palliative care in the United States. We review the essential elements of the doctrine of double effect, and emphasize the importance of pre-medicating patients before ventilator withdrawal (anticipatory dosing) and of titrating medications to the needs of the patient. The doctrine of double effect requires physicians to balance the risk of the patient suffering against the risk of hastening the patient's deathwhen titrating the medications used to provide comfort. We argue that the values and preferences of the patient should determine how these risks are balanced. We therefore agree with Billings that general anesthesia may be indicated for patients who prefer to minimize the risk of suffering while accepting a greater risk of having their death hastened. This approach would not be appropriate, however, for patients who place a higher value upon avoiding the risk of hastening death, even when this involves a greater risk of potential suffering.

Entities:  

Mesh:

Year:  2012        PMID: 22249031     DOI: 10.1097/CCM.0b013e3182413b8a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Incidence and Risk Model Development for Severe Tachypnea Following Terminal Extubation.

Authors:  Corey R Fehnel; Miguel Armengol de la Hoz; Leo A Celi; Margaret L Campbell; Khalid Hanafy; Ala Nozari; Douglas B White; Susan L Mitchell
Journal:  Chest       Date:  2020-04-28       Impact factor: 9.410

2.  [Immediate extubation or terminal weaning in ventilated intensive care patients after therapeutic goal change].

Authors:  U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-11-16       Impact factor: 0.840

3.  Terminal weaning or immediate extubation for withdrawing mechanical ventilation in critically ill patients (the ARREVE observational study).

Authors:  René Robert; Amélie Le Gouge; Nancy Kentish-Barnes; Alice Cottereau; Bruno Giraudeau; Mélanie Adda; Djillali Annane; Juliette Audibert; François Barbier; Patrick Bardou; Simon Bourcier; Jeremy Bourenne; Alexandre Boyer; François Brenas; Vincent Das; Arnaud Desachy; Jérôme Devaquet; Marc Feissel; Frédérique Ganster; Maïté Garrouste-Orgeas; Guillaume Grillet; Olivier Guisset; Rebecca Hamidfar-Roy; Anne-Claire Hyacinthe; Sebastien Jochmans; Mercé Jourdain; Alexandre Lautrette; Nicolas Lerolle; Olivier Lesieur; Fabien Lion; Philippe Mateu; Bruno Megarbane; Sybille Merceron; Emmanuelle Mercier; Jonathan Messika; Paul Morin-Longuet; Bénédicte Philippon-Jouve; Jean-Pierre Quenot; Anne Renault; Xavier Repesse; Jean-Philippe Rigaud; Ségolène Robin; Antoine Roquilly; Amélie Seguin; Didier Thevenin; Patrice Tirot; Isabelle Vinatier; Elie Azoulay; Jean Reignier
Journal:  Intensive Care Med       Date:  2017-09-22       Impact factor: 17.440

4.  Sedatives and Analgesics Given to Infants in Neonatal Intensive Care Units at the End of Life.

Authors:  Kanecia O Zimmerman; Christoph P Hornik; Lawrence Ku; Kevin Watt; Matthew M Laughon; Margarita Bidegain; Reese H Clark; P Brian Smith
Journal:  J Pediatr       Date:  2015-05-23       Impact factor: 6.314

5.  End of life in the intensive care unit: should French law be adapted?

Authors:  René Robert; Laurence Salomon; Lise Haddad; Jean-Pierre Graftieaux; Béatrice Eon; Didier Dreyfuss
Journal:  Ann Intensive Care       Date:  2014-02-25       Impact factor: 6.925

6.  Compassionate extubation for a peaceful death in the setting of a community hospital: a case-series study.

Authors:  Victor C Kok
Journal:  Clin Interv Aging       Date:  2015-04-04       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.